Genetic Approaches Look Beyond Oncogenes For Cancer Therapy Targets
This article was originally published in Start Up
A half decade of large-scale cancer genome sequencing has identified only one new and relatively common druggable oncogene target. But the genes that cause out-of-control proliferation also create problems for the cancer cells, which may then need to hijack normal cellular functions to help them survive. A research team used genetic screening to find such a dependency and showed that inhibiting the process could improve treatment.
You may also be interested in...
A recent report shows that some cancer cells may be more sensitive to chemotherapy because their mitochondria are primed to undergo programmed cell death. An assay that identifies the start of the process could help optimize the use of traditional chemo. And novel agents not potent enough to be used against tumors on their own could selectively prime tumors in this way as part of combination therapy.
Impaired calcium uptake is a hallmark of heart failure. The enzyme SERCA2a is known to play a critical role in maintaining the normal contractile function of those cells whose activity is decreased or disrupted in failing hearts. But its large size makes the enzyme a difficult drug target. Now, however, a research team has identified a small protein that interacts with SERCA2a after heart failure, which could open the door on a potential new approach to therapy.
New data point to a targeted strategy for treating a significant subset of liver cancers and importantly, provide a biomarker for identifying patients who could benefit from the therapy. It's based on the discovery of a correlation between amplification of a growth factor gene and overexpression of the gene's protein product -- a phenomenon that mirrors the way in which amplified Her2/neu gene expression promotes a subset of breast cancer, which led to the development of Herceptin.